Rick Bright, the ousted chief of the Biomedical Advanced Research and Development Agency, said he was pressured to steer millions of dollars to the clients of a well-connected consultant.

Provided by PR NewswireNov 5, 2024 10:00am BioVaxys to Participate in the US Government Biomedical Advanced Research and Development Authority (BARDA) Rapid Response Partnership Vehicle (RRPV ...

We are very pleased to receive the continued funding under the OTA with BARDA to support the development of our antifungal drug candidates fosmanogepix and BAL2062. Both compounds offer a novel ...

The Biden administration awarded the vaccine manufacturer a $590 million grant in January from the Biomedical Advanced Research and Development Authority. The funding followed another $176 million ...

News about Biomedical Advanced Research and Development Authority. Commentary and archival information about Biomedical Advanced Research and Development Authority from The New York Times.

BioVaxys to Participate in the US Government Biomedical Advanced Research and Development Authority (BARDA) Rapid Response Partnership Vehicle (RRPV) Vaccine Development Consortium ...

The RRPV is a multiple-purpose acquisition vehicle to facilitate end-to-end development of future medical countermeasures, from the early stage through the advanced development, procurement ...